714. Analysis of the Effect of Urine on the In Vitro Activity of Gepotidacin and Levofloxacin Against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus saprophyticus

BACKGROUND: Gepotidacin (GSK2140944) is a first in class novel triazaacenaphthylene bacterial type II topoisomerase inhibitor in clinical development for the treatment of gonorrhea and uncomplicated UTI (acute cystitis). Gepotidacin selectively inhibits bacterial DNA gyrase and topoisomerase IV by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Koeth, Laura M, DiFranco-Fisher, Jeanna M, Scangarella-Oman, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811144/
http://dx.doi.org/10.1093/ofid/ofz360.782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811144/
http://dx.doi.org/10.1093/ofid/ofz360.782

Ejemplares similares